Get started
Author

Jasmine K Sahni

Reduced narcotic and sedative utilization in a NICU after implementation of pain management guidelines
2017 · D Rana, B Bellflower, et al. · Journal of Perinatology · 41
A hospital perspective on the cost-effectiveness ofβ-Blockade for prophylaxis of atrial fibrillation after cardiothoracic surgery
2005 · Effie L Gillespie, C. Michael White, et al. · Clinical Therapeutics · 17
Retrospective Evaluation of Enoxaparin Dosing in Patients 48 Weeks' Postmenstrual Age or Younger in a Neonatal Intensive Care Unit
2012 · J Kevin Hicks, Chasity M Shelton, et al. · Annals of Pharmacotherapy · 13
Nebulized Furosemide in the Treatment of Bronchopulmonary Dysplasia in Preterm Infants
2011 · Jasmine Sahni, Stephanie J. Phelps · The Journal of Pediatric Pharmacology and Therapeutics · 13
Reveal Lite 2 Risk Assessment in Patients With Pulmonary Arterial Hypertension From the Griphon Study: a Post-hoc Analysis Demonstrates Association of Risk Status With Long-term Outcomes
2021 · RAYMOND BENZA, KELLY CHIN, et al. · CHEST Journal · 4
PDF
Preliminary experience from the ODYSSEY trial: Efficacy and safety of momelotinib in combination with luspatercept in patients with transfusion-dependent myelofibrosis
2025 · Prithviraj Bose, Jean-Christophe Ianotto, et al. · Blood · 2
PDF
Association between momelotinib exposure and hemoglobin improvement in patients with myelofibrosis and anemia: An exposure-response and time-to-event analysis
2025 · Vikas Gupta, Jose Torregrosa, et al. · Blood · 2
PDF
Association between hemoglobin (Hb) improvement and patient-reported outcomes (PROs) in patients (pts) with myelofibrosis (MF) and anemia: Post hoc pooled analysis of momelotinib (MMB) phase 3 trials.
2024 · Jeanne M. Palmer, Flora Mazerolle, et al. · Journal of Clinical Oncology · 2
Survival and clinical outcomes in patients with myelofibrosis and new or worsening anemia treated with ruxolitinib: A systematic review and meta-analysis
2025 · Andrew Kuykendall, Francesca Palandri, et al. · Blood · 1
PDF
Transfusion independence with momelotinib regardless of baseline erythropoietin levels in the Phase 3 SIMPLIFY-1 trial
2025 · Stephen Oh, Juan Carlos Hernandez Boluda, et al. · Blood · 1
PDF
Impact of new or worsening anemia and thrombocytopenia on clinical outcomes in JAK inhibitor–naive myelofibrosis patients treated with ruxolitinib
2025 · Vikas Gupta, Francesca Palandri, et al. · Blood · 1
Survival outcomes in ruxolitinib-treated patients with myelofibrosis following crossover to momelotinib: Application of the response to ruxolitinib at 6 months (RR6) prognostic model to SIMPLIFY-1
2025 · Raajit Rampal, Prithviraj Bose, et al. · Blood · 1
PDF
Time Required by Pharmacy Technicians to Reconstitute New versus Old Piperacillin/Tazobactam Formulations
2007 · Jasmine K Sahni, Joseph L Kuti, et al. · Journal of Pharmacy Technology · 1
Revatio (sildenafil citrate) for the treatment of pulmonary arterial hypertension.
2006 · Jasmine Sahni · PubMed · 1
Optimized dosing of momelotinib in myelofibrosis through quantitative medicine: a clinical commentary
2026 · Georgios Vlasakakis, Fernando Carreño, et al. · Leukemia & lymphoma/Leukemia and lymphoma
PDF
MDS-583: ATLAS: A Randomized, Double-Blind, Placebo-Controlled, Adaptive Seamless Phase 2/3 Study to Assess the Safety and Efficacy of Momelotinib in Patients With VEXAS Syndrome
2026 · David B Beck, Mael Heiblig, et al. · Clinical Lymphoma Myeloma & Leukemia
POSTER: MDS-583: ATLAS: A Randomized, Double-Blind, Placebo-Controlled, Adaptive Seamless Phase 2/3 Study to Assess the Safety and Efficacy of Momelotinib in Patients With VEXAS Syndrome
2026 · David B Beck, Mael Heiblig, et al. · Clinical Lymphoma Myeloma & Leukemia
POSTER: MPN-318: Characterization of Symptoms After Immediate Transition From Ruxolitinib to Momelotinib in Patients With Myelofibrosis: Post-Hoc Analyses of the Phase 3 SIMPLIFY-1 and SIMPLIFY-2 Trials
2026 · Pankit Vachhani, Alessandro Lucchesi, et al. · Clinical Lymphoma Myeloma & Leukemia
MPN-318: Characterization of Symptoms After Immediate Transition From Ruxolitinib to Momelotinib in Patients With Myelofibrosis: Post-Hoc Analyses of the Phase 3 SIMPLIFY-1 and SIMPLIFY-2 Trials
2026 · Pankit Vachhani, Alessandro Lucchesi, et al. · Clinical Lymphoma Myeloma & Leukemia
Impact of Hemoglobin Improvement on Survival in Patients With Myelofibrosis and Anemia Treated With Momelotinib in the SIMPLIFY ‐1 and MOMENTUM Trials
2026 · Francesca Palandri, Casey O'Connell, et al. · European Journal Of Haematology
Clinical outcomes with ruxolitinib in Janus kinase inhibitor–naive patients with myelofibrosis and new or worsening anemia or thrombocytopenia: post hoc analysis of the phase 3 SIMPLIFY-1 trial
2026 · Vikas Gupta, Francesca Palandri, et al. · NCODA Oncology and Hematology Meeting Abstracts
MPN-690: Clinical Outcomes With Momelotinib vs Ruxolitinib in Patients With Myelofibrosis Who Have Moderate Anemia: Subgroup Analysis of SIMPLIFY-1
2025 · Stephen Oh, Bart Scott, et al. · Clinical Lymphoma Myeloma & Leukemia
POSTER: MPN-690 Clinical Outcomes With Momelotinib vs Ruxolitinib in Patients With Myelofibrosis Who Have Moderate Anemia: Subgroup Analysis of SIMPLIFY-1
2025 · Stephen Oh, Bart Scott, et al. · Clinical Lymphoma Myeloma & Leukemia
MPN-085 Association Between Hemoglobin Improvement and Patient-Reported Outcomes in Patients With Myelofibrosis and Anemia: Post Hoc Pooled Analysis of Momelotinib Phase 3 Trials
2024 · Jeanne Palmer, Flora Mazerolle, et al. · Clinical Lymphoma Myeloma & Leukemia
Association Between Hemoglobin Improvement and Patient-Reported Outcomes in Patients With Myelofibrosis and Anemia: Post Hoc Pooled Analysis of Momelotinib Phase 3 Trials
2024 · Jeanne Palmer, Flora Mazerolle, et al. · Clinical Lymphoma Myeloma & Leukemia
Works count: 25
Citation count: 100
H-index: 4
I10-index: 4
Year
Topic
Type